- WuXi Biologics has launched the WuXia RidGS platform, a high-yield CHO expression system for therapeutic proteins.
- The platform utilizes ZFN technology and ensures stable productivity without antibiotics, achieving clonal expression levels exceeding 6 g/L for monoclonal antibodies.
WuXi Biologics (“WuXi Bio”) has announced the launch of its WuXia RidGS platform, aimed at improving the development of therapeutic proteins, particularly monoclonal antibodies (mAbs). This innovative platform employs a glutamine synthetase (GS)-knockout CHO expression system, which leverages zinc finger nucleases (ZFN) technology to target and knock out the endogenous GS gene in CHO cells.
The WuXia RidGS platform maintains the robust characteristics of the existing WuXia system, achieving average clonal expression levels exceeding 6 g/L for mAbs. It also supports the production of other therapeutic modalities, such as bispecific antibodies and Fc-fusion proteins, while ensuring stability and quality in protein production. Notably, WuXia RidGS operates without the need for antibiotics, allowing for stable productivity and uniform quality over extended periods.
Dr. Chris Chen, CEO of WuXi Biologics, stated, “With the launch of WuXia RidGS, we are pleased to offer a more efficient alternative for the development of advanced therapeutic proteins.” This initiative reflects WuXi Biologics’ ongoing commitment to developing tailored technology platforms that meet the evolving needs of its global clients, aiming to accelerate the delivery of high-quality biologics to patients.
Overview of outsourcing trends 
